The Trump administration has shelved a proposal that would have stymied egregious price hikes in the Medicare prescription drug program. It’s a major win for the drug industry, and a defeat for Trump’s goal of reducing drug prices. How ‘protected classes’ lead to skyrocketing prices The rule revolved around Medicare’s program for